FIRE1 raised $120 million for its Norm system — a heart failure monitor implant that seeks to keep patients out of the hospital. The post Irish Startup Snags $120M for Heart Failure Implant appeared first on MedCity News.
Contraline released promising new trial data showing that its male contraceptive gel has demonstrated safety and efficacy in the first two trial participants to reach the two-year mark. The company is aiming to earn the product’s FDA approval by the end of 2028, according to CEO Kevin Eisenfrats. The post Trial Data Shows ‘IUD for…
Accountability drives success, and for Kevin Theis, Director of Environmental Services (EVS) and Linen Services at MedStar Harbor Hospital, it’s a core value. His commitment to both team and personal accountability recently earned the EVS team a prestigious Certificate of Merit from the Association for the Health Care Environment (AHE). This national recognition honors environmental…
Sotyktu, which became the first TYK2 inhibitor to reach the market after its 2022 FDA approval in plaque psoriasis, now has positive data from two pivotal tests in psoriatic arthritis. Bristol Myers Squibb is trying to add new indications for the drug and stay ahead of competitors including Takeda Pharmaceutical. The post Bristol Myers Squibb’s…
By MATTHEW HOLT Two weeks ago I wrote an April Fool’s piece that claimed that Elon Musk and DOGE were going to nationalize American health care to save some money. That piece was half-joking but full-serious. If you look at what Musk is complaining about there are two major areas of “waste, fraud and abuse”…
Novo Nordisk’s monlunabant showed signs of neuropsychiatric side effects in a mid-stage diabetic kidney disease study, despite a drug design intended to favor hitting its target receptor in peripheral tissues rather than the brain. Neuro effects were also reported last year in a Phase 2 test of this pill in obesity. The post Oral Metabolic…
By GEORGE BEAUREGARD During my years in a bustling metropolitan primary care practice from 1992 to 2010, I recall only a handful of patients under 50 who developed cancer. Not surprisingly, these were mostly cases of Hodgkin’s and Non-Hodgkin’s lymphomas, myeloma, skin, and breast cancer. Fortunately, those few patients were wearing the mantle of cancer…
Many people don’t understand why pharmaceuticals cost so much money. Don’t pharmaceutical companies make a lot of money? The answer is ‘yes’, but only if the drugs are successful. A paper by Wouters et al. (2024) found that: Based on data for 361 of 558 new therapeutic agents approved over the study period (median follow-up…
Instead of an engineered peptide to activate gut receptors to trigger metabolic effects, Syntis’s technology forms a coating in intestines that has the effect of redirecting nutrients, mimicking an effect of gastric bypass surgery. In other obesity medicine news, Protagonist Therapeutics revealed a drug candidate that puts it in competition with Novo Nordisk and Eli…
Hospitals are facing increasingly burdensome policies from commercial insurers, leading to problems with cash flow and patient safety. Hospital executives think federal regulators need to enact stricter policies that require payers to operate on faster timelines, as well as provide more transparency into their reasons for denying claims. The post Payers Are Putting Profit Over…